KC
ABUS icon

Kades & Cheifetz’s Arbutus Biopharma ABUS Stock Holding History

Kades & Cheifetz’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$65.4K Hold
20,000
– – 0.03% 108
2024
Q3 		$77K Hold
20,000
– – 0.04% 94
2024
Q2 		$61.8K Hold
20,000
– – 0.04% 92
2024
Q1 		$51.6K Hold
20,000
– – 0.03% 90
2023
Q4 		$50K Hold
20,000
– – 0.04% 80
2023
Q3 		$40.6K Buy
+20,000
New +$41.9K 0.03% 74
2023
Q2 		– Sell
-20,000
Closed -$60.6K – 76
2023
Q1 		$60.6K Hold
20,000
– – 0.05% 76
2022
Q4 		$46.6K Buy
+20,000
New +$47.8K 0.04% 74

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Kades & Cheifetz's ABUS Position: Q4 2024 in Review

Kades & Cheifetz held its Arbutus Biopharma (ABUS) position steady in Q4 2024 at 20,000 shares worth $65.4K. The position accounts for 0.03% of the portfolio, ranked #108.

Kades & Cheifetz first reported a position in ABUS in Q4 2022 and has held it in 8 quarters since. The position peaked at $77K in Q3 2024. 153 funds tracked by Wall St. Rank hold ABUS as of Q4 2024.

  • Kades & Cheifetz held 20,000 shares of Arbutus Biopharma worth $65.4K as of Q4 2024.
  • Kades & Cheifetz left its Arbutus Biopharma share count unchanged in Q4 2024.
  • Arbutus Biopharma made up 0.03% of Kades & Cheifetz's portfolio in Q4 2024, its #108 holding.
  • Kades & Cheifetz first reported a position in Arbutus Biopharma in Q4 2022 and has held it in 8 quarters since.
  • Kades & Cheifetz's Arbutus Biopharma position peaked at $77K in Q3 2024.
  • 153 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2024.

Based on Kades & Cheifetz's 13F filing for Q4 2024, filed 13 Jan 2025.